{"id":872467,"date":"2025-08-07T07:36:34","date_gmt":"2025-08-07T11:36:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\/"},"modified":"2025-08-07T07:36:34","modified_gmt":"2025-08-07T11:36:34","slug":"y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\/","title":{"rendered":"Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p>PRINCETON, N.J., Aug.  07, 2025  (GLOBE NEWSWIRE) &#8212; Y-mAbs Therapeutics, Inc. (the \u201cCompany\u201d or \u201cY-mAbs\u201d) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, today announced it will report results for the second quarter 2025 before the market open on\u00a0Friday, August 8, 2025.<\/p>\n<p>In light of the previously announced transaction with affiliated entities of SERB Pharmaceuticals, Y-mAbs will not be hosting an earnings conference call.<\/p>\n<p>\n        <strong>About Y-mAbs<\/strong>\n      <\/p>\n<p>Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company\u2019s broad and advanced commercial product pipeline includes the anti-GD2 therapy DANYELZA<sup>\u00ae<\/sup> (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. The Company\u2019s technologies include its investigational Self-Assembly DisAssembly (\u201cSADA\u201d) Pretargeted Radioimmunotherapy Platform (\u201cPRIT\u201d) and bispecific antibodies generated using the Y-BiClone platform.<\/p>\n<p>SADA<sup>\u00ae<\/sup>, SADA PRIT<sup>\u2122<\/sup>, DANYELZA<sup>\u00ae<\/sup> and Y-mAbs<sup>\u00ae<\/sup> are registered trademarks of Y-mAbs Therapeutics, Inc.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzc0NCM3MDg2MDAyIzIwOTY3OTU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDg1ZmE5OTItZDVhZS00M2Y0LTliODAtMzQ0MDY5ZDFkNzNkLTExMDgzNjYtMjAyNS0wOC0wNy1lbg==\/tiny\/Y-mAbs-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>CONTACTS\r\n\r\nInvestor and Media Contacts:\r\n\r\nCourtney Dugan\r\nVP, Head of Investor Relations\r\ncdu@ymabs.com\r\n\r\nAaron Palash \/ Fouad Boutros\r\nJoele Frank, Wilkinson Brimmer Katcher\r\napalash@joelefrank.com\r\nfboutros@joelefrank.com\r\n212-355-4449<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) &#8212; Y-mAbs Therapeutics, Inc. (the \u201cCompany\u201d or \u201cY-mAbs\u201d) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, today announced it will report results for the second quarter 2025 before the market open on\u00a0Friday, August 8, 2025. In light of the previously announced transaction with affiliated entities of SERB Pharmaceuticals, Y-mAbs will not be hosting an earnings conference call. About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company\u2019s broad and advanced commercial product pipeline includes the anti-GD2 therapy DANYELZA\u00ae (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-872467","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) &#8212; Y-mAbs Therapeutics, Inc. (the \u201cCompany\u201d or \u201cY-mAbs\u201d) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, today announced it will report results for the second quarter 2025 before the market open on\u00a0Friday, August 8, 2025. In light of the previously announced transaction with affiliated entities of SERB Pharmaceuticals, Y-mAbs will not be hosting an earnings conference call. About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company\u2019s broad and advanced commercial product pipeline includes the anti-GD2 therapy DANYELZA\u00ae (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed &hellip; Continue reading &quot;Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-07T11:36:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzc0NCM3MDg2MDAyIzIwOTY3OTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025\",\"datePublished\":\"2025-08-07T11:36:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\\\/\"},\"wordCount\":186,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNzc0NCM3MDg2MDAyIzIwOTY3OTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\\\/\",\"name\":\"Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNzc0NCM3MDg2MDAyIzIwOTY3OTU=\",\"datePublished\":\"2025-08-07T11:36:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNzc0NCM3MDg2MDAyIzIwOTY3OTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNzc0NCM3MDg2MDAyIzIwOTY3OTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\/","og_locale":"en_US","og_type":"article","og_title":"Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025 - Market Newsdesk","og_description":"PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) &#8212; Y-mAbs Therapeutics, Inc. (the \u201cCompany\u201d or \u201cY-mAbs\u201d) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, today announced it will report results for the second quarter 2025 before the market open on\u00a0Friday, August 8, 2025. In light of the previously announced transaction with affiliated entities of SERB Pharmaceuticals, Y-mAbs will not be hosting an earnings conference call. About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company\u2019s broad and advanced commercial product pipeline includes the anti-GD2 therapy DANYELZA\u00ae (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed &hellip; Continue reading \"Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-07T11:36:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzc0NCM3MDg2MDAyIzIwOTY3OTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025","datePublished":"2025-08-07T11:36:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\/"},"wordCount":186,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzc0NCM3MDg2MDAyIzIwOTY3OTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\/","name":"Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzc0NCM3MDg2MDAyIzIwOTY3OTU=","datePublished":"2025-08-07T11:36:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzc0NCM3MDg2MDAyIzIwOTY3OTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzc0NCM3MDg2MDAyIzIwOTY3OTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/872467","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=872467"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/872467\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=872467"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=872467"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=872467"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}